Successful treatment of extremely severe fetal anemia due to Kell alloimmunization

Obstetrics and Gynecology

Volumn 100, Issue 5 SUPPL., 2002, Pages 1102-1105

  Collinet, P ^a   Subtil, D ^a   Puech, F ^a   Vaast, P ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ALLOIMMUNIZATION; ANEMIA; APLASTIC ANEMIA; ARTICLE; BLOOD GROUP KELL SYSTEM; CASE REPORT; CESAREAN SECTION; DISEASE SEVERITY; FEMALE; FETUS; FETUS DISEASE; HUMAN; HYDROPS; INTRAUTERINE BLOOD TRANSFUSION; MATERNAL PLASMA; PLASMAPHERESIS; PREGNANCY; PRIORITY JOURNAL; ULTRASOUND; UMBILICAL VEIN;

EID: 0036848083     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(02)02143-9     Document Type: Article

References (8)

1. Nicolaides K.H., Soothill P.W., Clewell W.H., Rodeck C.H., Mibashan R.S., Campbell S. Fetal haemoglobin measurement in the assessment of red cell isoimmunisation. Lancet. 1:1988;1073-1075.
2. Grab D., Paulus W.E., Bommer A., Buck G., Terinde R. Treatment of fetal erythroblastosis by intravascular transfusions Outcome at 6 years. Obstet Gynecol. 93:1999;165-168.
3. Ulm B., Ulm M.R., Deutinger J., Bernaschek G. Twenty-four cordocenteses in one woman. Fetal Diagn Ther. 14:1999;283-285.
4. Forestier F., Daffos F., Catherine N., Renard M., Andreux J.P. Developmental hematopoiesis in normal human fetal blood. Blood. 77:1991;2360-2363.
5. Graham-Pole J., Barr W., Willoughby M.L. Continuous-flow plasmapheresis in management of severe rhesus disease. Br Med J. 1:1977;1185-1188.
6. Schumacher B., Moise K.J. Jr. Fetal transfusion for red blood cell alloimmunization in pregnancy. Obstet Gynecol. 88:1996;137-150.
7. Doyle L.W., Kelly E.A., Rickards A.L., Ford G.W., Callanan C. Sensorineural outcome at 2 years for survivors of erythroblastosis treated with fetal intravascular transfusions. Obstet Gynecol. 81:1993;931-935.
8. Hudon L., Moise K.J. Jr, Hegemier S.E., Hill R.M., Moise A.A., Smith E.O., et al. Long-term neurodevelopmental outcome after intrauterine transfusion for the treatment of fetal hemolytic disease. Am J Obstet Gynecol. 179:1998;858-863.